Stock Mover of the Day: Is Selling Affimed NV Here a Winning Strategy?

Stock Mover of the Day: Is Selling Affimed NV Here a Winning Strategy?

The stock of Affimed NV (NASDAQ:AFMD) reached all time low today, Oct, 13 and still has $2.12 target or 10.00% below today’s $2.36 share price. This indicates more downside for the $78.16M company. This technical setup was reported by Barchart.com. If the $2.12 PT is reached, the company will be worth $7.82 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 92,837 shares traded hands. Affimed NV (NASDAQ:AFMD) has declined 35.56% since March 10, 2016 and is downtrending. It has underperformed by 43.08% the S&P500.

Analysts await Affimed NV (NASDAQ:AFMD) to report earnings on November, 8. They expect $-0.25 EPS, up 7.41% or $0.02 from last year’s $-0.27 per share. After $-0.27 actual EPS reported by Affimed NV for the previous quarter, Wall Street now forecasts -7.41% EPS growth.

Affimed NV (NASDAQ:AFMD) Ratings Coverage

Out of 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. Affimed Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Laidlaw initiated the stock with “Buy” rating in Thursday, December 10 report. The stock of Affimed NV (NASDAQ:AFMD) has “Outperform” rating given on Thursday, August 6 by Oppenheimer. The firm has “Sell” rating given on Monday, August 10 by Zacks. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. As per Wednesday, September 9, the company rating was initiated by Jefferies. The company was upgraded on Thursday, September 3 by Zacks. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo. The rating was downgraded by Leerink Swann to “Market Perform” on Friday, August 12. Leerink Swann downgraded the stock to “Market Perform” rating in Thursday, May 19 report. The firm has “Hold” rating given on Thursday, May 19 by Jefferies.

According to Zacks Investment Research, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.”

More recent Affimed NV (NASDAQ:AFMD) news were published by: Quotes.Wsj.com which released: “Affimed NV AFMD (US: Nasdaq)” on September 05, 2014. Also Zacks.com published the news titled: “Should You Get Rid of Affimed N.V. (AFMD) Now?” on August 14, 2015. Globenewswire.com‘s news article titled: “Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination …” with publication date: January 25, 2016 was also an interesting one.

AFMD Company Profile

Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Firm generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). The Company’s bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment